AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

โ† Trials
๐Ÿงช

Clinical Trial Evaluating the Impact of an Intensive Rehabilitation Program Combined With Tendon Vibratory Stimulation on Functional Balance in Individuals With Charcot-Marie-Tooth Disease Type 1A

RecruitingNAAges 18 Years - 65 YearsAllUGECAM PACA et Corse
๐Ÿ’ฌ

In plain words

What the trial is, and whether it could suit you

Charcot-Marie-Tooth (CMT) disease is caused by a genetic abnormality involving the PMP22 gene, resulting in demyelination of the peripheral nerves. Demyelination leads to sensorimotor impairment and causes progressive muscle weakness and tendon contractures, initially affecting the lower limbs. Consequently, individuals with CMT experience balance impairments and gait disturbances, including ankle instability, foot drop, and postural instability, which lead to frequent falls and reduced quality of life. Currently, there is no disease-modifying treatment for CMT. Several rehabilitation approaches have been proposed, including endurance training and muscle strengthening programs, to improve independence in activities of daily living. However, rehabilitation practices for individuals with CMT remain poorly standardized, and there is still a lack of clearly defined rehabilitation protocols,

Sign in to get the eligibility rules as simple questions to take to your doctor.

๐Ÿ“‹ Eligibility rules (as published)
Inclusion Criteria: * Individuals with genetically confirmed Charcot-Marie-Tooth disease type 1A (CMT1A), characterized by PMP22 gene duplication on chromosome 17 (17p11.2). * Age between 18 and 65 years. * Overall Neuropathy Limitations Scale (ONLS) score between 2 and 3/7 for the lower limbs. * Affiliation with a social security/health insurance system. * Written informed consent voluntarily provided after receiving information regarding the study objectives, procedures, and potential risks. Exclusion Criteria: * Comorbidities causing peripheral neuropathy (e.g., diabetes, renal failure, medication-induced neuropathy). * Balance or gait disorders due to another cause. * Individuals without a permanent residence. * Individuals deprived of liberty by judicial or administrative decision or under legal guardianship. * Individuals unable to understand the study objectives and procedures or unable to provide informed consent. * Individuals unable to complete all study procedures. * Previous use of the Vibramoov device. * Pregnant women or women planning to become pregnant during the study period. * Concurrent participation in another research study.
๐Ÿ’Š

What it tests

  • Multidisciplinary rehabilitation program
๐Ÿ“

Where

1 site
IUR Valmante Sud
Marseille, France
๐Ÿค Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible โ€” always decide together with your own doctor.
๐Ÿ›ก๏ธ

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it โ€” not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use ยท Privacy